Investing In Psychedelics

THE PRICE –

Free

THE DATE –

Thu, June 18, 2020

4:00 AM – 8:00 AM AEST

THE RATING –

THE BLURB –

CFN Media is teaming up with The CSE to host the online event that will bring together leading financial experts and CEOs on live panels for an in-depth view into the value proposition of the emerging psychedelics market. Attendees will see and hear from bankers and funds from across the globe discussing the best investment opportunities and their due diligence processes. CEOs from private and publicly listed psychedelics companies will share their approach to navigating the capital markets to build market defining business models.

Leading up to the live event, registrants will receive pre-recorded one-on-one interviews with the industry’s preeminent medical experts, thought leaders and CEO’s beginning on May 27, 2020. These video ‘micro sessions’ will provide insights into the history of psychedelics in medicine, current clinical applications and the business models poised to seize market share.

June 17th Investing in Psychedelics LIVE EVENT!

A full afternoon of panel discussions amongst bankers, thought leaders and participating companies.

Bankers / Brokers

Atai Life Sciences – Aaron Weaver (Senior General Counsel)
Haywood Securities – Bill O’Hara (CFA & Managing Director)
TCF – Henri Sant-Cassia (Founding Partner)

Private Companies

Bright Minds Biosciences – Ian McDonald (Founder)
CB Therapeutics – Sher Ali Butt (Co-Founder & CEO)
Entheon Biomedical – Timothy Ko (CEO)
Field Trip Health – Ronan Levy (Founder & Executive Chairman)
Mindleap Health – Nikolai Vassev (Founder)
PharmaTher – Fabio Chianelli (CEO)
Psygen Labs – Danny Motyka (CEO)
Psyched Wellness – Jeff Stevens (CEO & Director)
Pure Extracts – Ben Nikolaevsky (CEO)
Silo Wellness – Mike Arnold (CEO & Founder)

Public Companies

Champignon Brands (CSE:SHRM) – Dr. Roger McIntyre (CEO)
Hollister Biosciences (CSE:HOLL) – Carl Saling (Founder & CEO), Alex Somjen (President), and Dr. Nikos C. Apostolopoulos (CSO of AlphaMind Brands)
Pharmadrug (CSE:BUZZ) – Daniel Cohen (CFA)
Psilocin Pharma (Division of Revive Therapeutics) – Derrick Welsh (Founder)
Red Light Holland (CSE:TRIP) – Todd Shapiro (CEO)
Revive Therapeutics (CSE:RVV) – Michael Frank (Chairman & CEO)

Micro Sessions Agenda

Each week registrants will receive links to one-on-one video interviews with thought leaders in the psychedelics space, offering insights into the history, applications, and future of the sector.

May 28th

Richard Carleton, CEO of the Canadian Securities Exchange, discusses this emerging sector and how to navigate it through listings and the capital markets.

Bruce Linton, Chairman of the Advisory Board for Red Light Holland Corp. (CSE:TRIP), discusses the space and its opportunities.

June 3rd

Dr. Dennis McKenna, Director of Ethnopharmacology at the Heffter Research Institute, provides an in-depth overview of the history of psychedelics.

Dr. Roger McIntyre, CEO of Champignon Brands (CSE:SHRM), gives an in-depth preview to the application of psychedelics and their therapeutic uses.

Dr. Nikos Apostolopoulos, CSO of AlphaMind Brands, talks about therapeutic applications and AlphaMind’s recent acquisition by Hollister Biosciences (CSE: HOLL).

June 10th

CEO clips from each participating company showcase the pioneering work they’re doing in the world of neuro-pharmaceuticals.

Also, check out our event Virtual Industry Updates: The Rise of the Psychedelics Sector in partnership with MNP LLP and Aird & Berlis LLP coming up on June 10th.